Vinva Investment Management Ltd Acquires 122,959 Shares of Pfizer Inc. $PFE

Vinva Investment Management Ltd lifted its holdings in Pfizer Inc. (NYSE:PFE) by 46.0% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 390,489 shares of the biopharmaceutical company’s stock after buying an additional 122,959 shares during the quarter. Vinva Investment Management Ltd’s holdings in Pfizer were worth $9,446,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in PFE. Westbourne Investments Inc. acquired a new position in Pfizer during the 1st quarter valued at about $2,411,000. Bourne Lent Asset Management Inc. grew its position in shares of Pfizer by 90.8% during the 2nd quarter. Bourne Lent Asset Management Inc. now owns 38,255 shares of the biopharmaceutical company’s stock worth $927,000 after buying an additional 18,200 shares during the period. Strs Ohio bought a new stake in shares of Pfizer during the first quarter worth approximately $49,968,000. IFM Investors Pty Ltd lifted its holdings in Pfizer by 3.8% in the second quarter. IFM Investors Pty Ltd now owns 1,127,143 shares of the biopharmaceutical company’s stock valued at $27,322,000 after buying an additional 41,263 shares during the period. Finally, Intrua Financial LLC boosted its stake in Pfizer by 17.4% in the first quarter. Intrua Financial LLC now owns 78,392 shares of the biopharmaceutical company’s stock valued at $1,986,000 after acquiring an additional 11,643 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have commented on the stock. Scotiabank assumed coverage on shares of Pfizer in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $30.00 target price for the company. Citigroup lifted their price objective on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 6th. UBS Group reissued a “neutral” rating and issued a $28.00 target price on shares of Pfizer in a research note on Wednesday, October 1st. Guggenheim boosted their target price on Pfizer from $33.00 to $35.00 and gave the stock a “buy” rating in a research report on Monday. Finally, Bank of America increased their price target on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a report on Friday, October 3rd. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $28.39.

Pfizer Price Performance

Shares of NYSE PFE opened at $25.72 on Thursday. The company has a fifty day moving average price of $24.94 and a 200 day moving average price of $24.55. The firm has a market cap of $146.21 billion, a PE ratio of 13.68, a PEG ratio of 0.81 and a beta of 0.54. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $27.69.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, beating analysts’ consensus estimates of $0.79 by $0.08. The company had revenue of $16.65 billion for the quarter, compared to analyst estimates of $16.94 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be paid a $0.43 dividend. The ex-dividend date is Friday, November 7th. This represents a $1.72 dividend on an annualized basis and a yield of 6.7%. Pfizer’s dividend payout ratio (DPR) is currently 100.00%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.